Asset Details
Do you wish to reserve the book?
Incretin Mimetics as Potential Therapeutics for Concussion and Traumatic Brain Injury: A Narrative Review
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Incretin Mimetics as Potential Therapeutics for Concussion and Traumatic Brain Injury: A Narrative Review
Do you wish to request the book?
Incretin Mimetics as Potential Therapeutics for Concussion and Traumatic Brain Injury: A Narrative Review
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Incretin Mimetics as Potential Therapeutics for Concussion and Traumatic Brain Injury: A Narrative Review
2025
Overview
Traumatic brain injury (TBI) represents a significant health concern, with an estimated 70 million annual cases worldwide. Mild brain trauma (concussions) is the most common TBI (81%), followed by moderate (11%) and severe (8%). Cytokine release and neuroinflammation after TBI may cause blood–brain barrier and tissue damage, triggering unfavorable outcomes, including disabilities and mortality. Current TBI treatments, focused on preventing secondary injury, are limited and insufficient. Therefore, new therapeutic approaches are necessary. A growing body of recent literature supports the potential use of incretins: glucagon-like peptide-1, glucose-dependent insulinotropic peptide, and glucagon receptor agonists, as potent neurotrophic/neuroprotective agents. Experiments performed in cellular and animal models, and a limited number of clinical studies, provide evidence that incretins might be a novel and effective treatment for TBI. Incretin-based compounds have already been shown to be safe and efficacious for the treatment of type 2 diabetes mellitus in humans. Therefore, incretins are ideal candidates for rapid evaluation in clinical trials of TBI and might become a novel therapeutic tool for a condition that has very few disease modifying treatments available. Well-designed human clinical trials are urgently needed to determine optimal dosing, timing, and patient selection for effective incretin use in concussion and TBI.
Publisher
MDPI AG,Multidisciplinary Digital Publishing Institute (MDPI)
Subject
/ Animals
/ Brain
/ Brain Concussion - drug therapy
/ Brain Concussion - metabolism
/ Brain Injuries, Traumatic - drug therapy
/ Brain Injuries, Traumatic - metabolism
/ Diabetes
/ Edema
/ Glucagon
/ Glucagon-Like Peptide 1 - therapeutic use
/ Humans
/ Memory
/ Neuroprotective Agents - pharmacology
/ Neuroprotective Agents - therapeutic use
/ Obesity
/ Review
/ Trauma
